☆ 4.5 Review

Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis

JOURNAL OF HEADACHE AND PAIN (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Otorhinolaryngology

Otolaryngology-Specific Symptoms May Be Highly Observed in Patients With a History of Covid-19 Infection After Inactivated Coronavirus Vaccination

Hakan Avci et al.

Summary: This study evaluated the occurrence of otolaryngology-specific symptoms and possible side effects in patients who had a Covid-19 infection in the last 6 months before receiving the Covid-19 vaccine. The results showed that patients with a history of Covid-19 infection were more likely to experience symptoms such as loss of smell and taste, nasal congestion, rhinorrhea, sore throat, and hearing loss.

ENT-EAR NOSE & THROAT JOURNAL (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1 January and 28 February 2021

Andrea Ossato et al.

Summary: This study investigated the adverse events following vaccination with the Comirnaty vaccine in individuals who were previously infected with COVID-19 and those who were not. The results showed that participants who had previously been infected experienced more side effects after the first dose, but fewer side effects after the second dose, compared to those who had not been previously infected. Most of the side effects identified in this study were consistent with reports from the manufacturer and the US Food and Drug Administration.

EUROPEAN JOURNAL OF HOSPITAL PHARMACY (2023)

添加到收藏夹

Article Clinical Neurology

COVID-19-related headache and sinonasal inflammation: A longitudinal study analysing the role of acute rhinosinusitis and ICHD-3 classification difficulties in SARS-CoV-2 infection

Marcin Straburzynski et al.

Summary: This study found a high prevalence of headache symptoms among COVID-19 patients, which were significantly associated with acute rhinosinusitis symptoms. Headache in these patients could be attributed to systemic viral infection rather than acute rhinosinusitis alone.

CEPHALALGIA (2022)

添加到收藏夹

Article Clinical Neurology

Activation of the trigeminal system as a likely target of SARS-CoV-2 may contribute to anosmia in COVID-19

Karl Messlinger et al.

Summary: Clinical publications consistently show that headache is a common and debilitating symptom in patients with COVID-19, often exhibiting migraine-like characteristics. Studies suggest that activation of the trigeminal nerve may contribute to both headache and anosmia in COVID-19 patients.

CEPHALALGIA (2022)

添加到收藏夹

Article Clinical Neurology

The characteristics of COVID-19 vaccine-related headache: Clues gathered from the healthcare personnel in the pandemic

Esme Ekizoglu et al.

Summary: Headache is a common adverse event following COVID-19 vaccination, with 30.6% of healthcare workers affected, predominantly females with pre-existing primary headaches, thyroid disorders, headache during COVID-19, or headache related to the influenza vaccine.

CEPHALALGIA (2022)

添加到收藏夹

Article Clinical Neurology

Incidence of headache after COVID-19 vaccination in patients with history of headache: A cross-sectional study

Koji Sekiguchi et al.

Summary: In a questionnaire survey conducted from April to May 2021, participants with a history of migraine and non-migrainous headache were found to have a higher incidence of headaches after COVID-19 vaccination compared to healthy controls.

CEPHALALGIA (2022)

添加到收藏夹

Article Urology & Nephrology

The effect of a single dose of BNT162b2 vaccine on the incidence of severe COVID-19 infection in patients on chronic hemodialysis: a single-centre study

Gabor Cserep et al.

Summary: This single-center study found that the BNT162b2 vaccine was safe and effective in HD patients, providing significant protection against infection even after the first dose. No life-threatening allergic reactions or other serious side effects were observed post-vaccination.

CLINICAL AND EXPERIMENTAL NEPHROLOGY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Survey data of COVID-19 vaccine side effects among hospital staffin a national referral hospital in Indonesia

Dovy Djanas et al.

Summary: This study analyzed survey data on COVID-19 vaccine side effects among hospital staff in a national referral hospital in Indonesia, covering a wide range of side effects symptoms. A total of 840 responses were collected, and data analysis was conducted using IBM version 25.0.

DATA IN BRIEF (2021)

添加到收藏夹

Article Respiratory System

Side effects and antibody titer transition of the BNT162b2 messenger ribonucleic acid coronavirus disease 2019 vaccine in Japan

Takehiro Izumo et al.

Summary: The BNT162b2 mRNA COVID-19 vaccine appears to be safe for Japanese individuals, with an increase in antibody titer observed after two doses. Side effects were reported, with a higher incidence in females compared to males, and a decrease in frequency with age. Further nationwide studies are needed to confirm these findings.

RESPIRATORY INVESTIGATION (2021)

添加到收藏夹

Article Infectious Diseases

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

Shengli Xia et al.

Summary: The inactivated SARS-CoV-2 vaccine, BBIBP-CorV, demonstrated safety and immunogenicity in two age groups. Humoral responses against SARS-CoV-2 were induced in all vaccine recipients by day 42. A two-dose immunisation with 4 mu g vaccine on days 0 and 21 or days 0 and 28 achieved higher neutralising antibody titres compared to other dosing schedules.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Neurosciences

Multiple Neuroinvasive Pathways in COVID-19

Dmitri Bougakov et al.

Summary: COVID-19 is a highly infectious viral disease caused by the novel coronavirus SARS-CoV-2, with impacts extending beyond respiratory system to multiple organs, including the brain. Infection can occur through axonal transport via the olfactory nerve and crossing of the blood-brain barrier, leading to various neurological symptoms and potential long-term cognitive impairments. Rigorous longitudinal follow-up and patient registries are needed to understand and address the long-term neurocognitive sequelae of COVID-19.

MOLECULAR NEUROBIOLOGY (2021)

添加到收藏夹

Article Health Care Sciences & Services

COVID-19 vaccination among Spanish nephrologists: Acceptance and side effects

B. Quiroga et al.

Summary: The majority of Spanish nephrologists have received Covid-19 vaccines, with common side effects including local reactions, myalgia, tiredness, and headache. Age and prior Covid-19 infection were predictors of vaccination side effects.

JOURNAL OF HEALTHCARE QUALITY RESEARCH (2021)

添加到收藏夹

Review Clinical Neurology

Headache as a Symptom of COVID-19: Narrative Review of 1-Year Research

Edoardo Caronna et al.

Summary: Headache is a common symptom of COVID-19 and may involve activation of the trigeminovascular system. Research on COVID-19 headache not only helps to understand COVID-19 better but also advances knowledge on secondary and primary headaches.

CURRENT PAIN AND HEADACHE REPORTS (2021)

添加到收藏夹

Review Clinical Neurology

Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19)

Biyan Nathanael Harapan et al.

Summary: The novel coronavirus SARS-CoV-2 causing COVID-19 has become a significant global challenge. In addition to respiratory symptoms, COVID-19 can also lead to neurological symptoms and complications. Further research is needed to understand the impact of neurological symptoms on the disease progression.

JOURNAL OF NEUROLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Sara Y. Tartof et al.

Summary: This study aimed to assess the overall and variant-specific effectiveness of the BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19-related hospital admissions among members of a healthcare system in California. The effectiveness of the vaccine remained high against hospital admissions even up to 6 months after full vaccination, despite a decline in effectiveness against SARS-CoV-2 infections over time, which was likely due to waning immunity rather than the delta variant escaping vaccine protection.

LANCET (2021)

添加到收藏夹

Editorial Material Clinical Neurology

Virtual Issue: COVID-19 and headache

Sarah M. Bobker et al.

HEADACHE (2021)

添加到收藏夹

Article Medicine, General & Internal

A snapshot global survey on side effects of COVID-19 vaccines among healthcare professionals and armed forces with a focus on headache

Armando Perrotta et al.

Summary: The survey among HCPs and AFP showed that COVID-19 vaccines, both mRNA and AdV, were safe and well tolerated with less and milder side effects reported.

PANMINERVA MEDICA (2021)

添加到收藏夹

Article Medicine, General & Internal

Description of symptom course in a telemedicine monitoring clinic for acute symptomatic COVID-19: a retrospective cohort study

James B. O'Keefe et al.

Summary: Describing the disease course and predicting duration of symptoms in a cohort of outpatient COVID-19 patients, this retrospective study found that initial symptom severity is a significant predictor of disease duration for most considered symptoms, with persistent symptoms common across categories.

BMJ OPEN (2021)

添加到收藏夹

Review Hematology

COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome

Massimo Franchini et al.

Summary: This concise review summarizes the epidemiologic and pathogenic mechanisms of vaccine-associated immune thrombosis and thrombocytopenia (VITT). A total of 40 VITT cases have been reported, emphasizing the need for continuous pharmacovigilance monitoring to collect more data and optimize patient management.

EUROPEAN JOURNAL OF HAEMATOLOGY (2021)

添加到收藏夹

Article Immunology

Safety of an inactivated SARS-CoV-2 vaccine among healthcare workers in China

Mei-Xian Zhang et al.

Summary: The study aimed to assess the safety of the CoronaVac vaccine among healthcare workers, finding a low incidence of adverse reactions with localized pain at the injection site being the most common, indicating an acceptable safety profile for the vaccine among this population.

EXPERT REVIEW OF VACCINES (2021)

添加到收藏夹

Article Infectious Diseases

Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers

Renuka A. K. Kadali et al.

Summary: A study on the side effects of the BNT162b2 mRNA vaccine for COVID-19 among healthcare workers revealed that most of the vaccinated individuals experienced some symptoms post vaccination, but the majority still intended to receive the second dose.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response

Yael Peled et al.

Summary: The study investigated the safety and efficacy of BNT162b2 vaccine in heart transplant recipients, showing a low rate of adverse events and some individuals developing antibody responses. The presence of IgG anti-RBD antibodies was associated with neutralizing SARS-CoV-2 pseudo-virus, but certain immunosuppressive regimens may impact the odds of an antibody response. Further research is needed to determine the optimal observation period for antibody response in immunocompromised individuals.

JOURNAL OF HEART AND LUNG TRANSPLANTATION (2021)

添加到收藏夹

Article Oncology

Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution

Fulvia Pimpinelli et al.

Summary: The study assessed the safety and immunogenicity of the BNT162b2 mRNA vaccine in hematological patients, finding lower response rates in multiple myeloma patients. It suggests that these patients should continue to maintain protective measures and monitor vaccine effectiveness post-vaccination.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study

Jitao Wang et al.

Summary: The study demonstrates that COVID-19 vaccination is safe and immunogenic in patients with non-alcoholic fatty liver disease (NAFLD). Most adverse reactions post-vaccination are mild and transient.

JOURNAL OF HEPATOLOGY (2021)

添加到收藏夹

Article Virology

Non-life-threatening adverse effects with COVID-19 mRNA-1273 vaccine: A randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms

Renuka Ananth Kalyan Kadali et al.

Summary: A study investigated the side effects of the mRNA-1273 vaccine among healthcare workers, finding that most recipients experienced one or more symptoms post-vaccination, but the majority were able to continue their daily activities unaffected. Despite a wide range of reported symptoms, the vast majority of healthcare workers did not plan to skip the second dose of the vaccine, indicating high acceptance for the vaccine.

JOURNAL OF MEDICAL VIROLOGY (2021)

添加到收藏夹

Article Infectious Diseases

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials

Shilong Yang et al.

Summary: The results from Phase 1 and Phase 2 trials of the COVID-19 vaccine ZF2001 show that the vaccine is well tolerated and immunogenic, supporting the use of a 25 microgram dose in a three-dose schedule for large-scale evaluation in a Phase 3 trial.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Infectious Diseases

Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2 dose-ranging study ,

Paul A. Goepfert et al.

Summary: The CoV2 preS dTM vaccine is being developed against SARS-CoV-2 and the interim results of the first-in-human study show lower than expected immune responses, especially in older age groups, and high reactogenicity after the second dose. Further development of the AS03-adjuvanted candidate vaccine will focus on identifying the optimal antigen formulation and dose.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Infectious Diseases

Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial

Keith J. Chappell et al.

Summary: The study evaluated the safety and immunogenicity of a novel COVID-19 vaccine, showing promising results in both aspects. Adverse reactions were minimal, and the vaccine elicited antigen-specific responses regardless of the dosage.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Infectious Diseases

Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study

Cristina Menni et al.

Summary: This study investigated the safety and effectiveness of the BNT162b2 and ChAdOx1 nCoV-19 vaccines in a UK community setting. The results showed that the frequencies of side effects from these vaccines were lower than reported in clinical trials, and a significant reduction in the risk of SARS-CoV-2 infection was observed starting at 12 days after vaccination.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Clinical Neurology

COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021

Anat Achiron et al.

Summary: The study shows that the COVID-19 BNT162b2 vaccine is safe for patients with MS, with no increased risk of relapse activity observed after vaccination.

MULTIPLE SCLEROSIS JOURNAL (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19

Brian J. Ward et al.

Summary: This study reported the interim safety and immunogenicity data of a plant-produced COVID-19 vaccine candidate at Day 42. The results showed good tolerability of all formulations and induction of immune responses, supporting further evaluation of the vaccine candidate.

NATURE MEDICINE (2021)

添加到收藏夹

Article Transplantation

Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared with healthy controls

Benedikt Simon et al.

Summary: HD patients had significantly lower anti-SARS-CoV-2 S antibody titres compared to controls 21 days after vaccination. The HD group experienced fewer adverse events than the control group. There was no correlation between the antibody response to Hepatitis B vaccination and the SARS-CoV-2 vaccine.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons

Tom T. Shimabukuro et al.

Summary: Preliminary data indicates that there are no obvious safety signals among pregnant women who received mRNA Covid-19 vaccines, but more data is needed for further confirmation. Adverse reactions such as injection-site pain were reported more frequently in pregnant women, but most pregnancies resulted in live births with some cases of preterm birth and small size for gestational age.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

V. Shinde et al.

Summary: The NVX-CoV2373 vaccine showed efficacy in preventing Covid-19, with higher vaccine efficacy observed among HIV-negative participants. Most infections were caused by the B.1.351 variant.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Safety survey by clinical pharmacists on COVID-19 vaccination from a single center in China

Guangfei Wang et al.

Summary: This study highlighted the important role and value of clinical pharmacists in the implementation of COVID-19 vaccination through investigating and analyzing the safety of COVID-19 vaccination in 2305 individuals. The common adverse reactions during vaccination were mostly mild and tolerable, indicating good safety of the inactivated COVID-19 vaccine.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)

添加到收藏夹

Article Medicine, General & Internal

Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic

Abanoub Riad et al.

Summary: The study conducted a survey on the side effects of the Pfizer-BioNTech COVID-19 vaccine among healthcare workers in the Czech Republic, revealing common side effects such as injection site pain, fatigue, and headache. Younger age groups and individuals who received two doses of the vaccine were more likely to experience side effects, with the overall prevalence of side effects higher than reported by the manufacturer.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Article Immunology

Analysis of Thrombotic Adverse Reactions of COVID-19 AstraZeneca Vaccine Reported to EudraVigilance Database

Mansour Tobaiqy et al.

Summary: The development of safe and effective vaccines against COVID-19 is crucial in the fight against the pandemic. Although some thrombotic adverse reactions were associated with the Oxford-AstraZeneca vaccine, the European Medicines Agency affirmed the vaccine's safety and effectiveness, with the benefits outweighing the risks. Conducting further analyses based on more detailed thrombotic adverse event reports may help evaluate causality with higher specificity.

VACCINES (2021)

添加到收藏夹

Article Immunology

The Incidence and Severity of Post-Vaccination Reactions after Vaccination against COVID-19

Izabela Jeskowiak et al.

Summary: Vaccination is key in limiting the spread of COVID-19, with Poland implementing a National Vaccination Program to ensure safe and effective vaccination among its citizens. Research suggests the need to verify GIS statistical data on post-vaccination reactions, as healthcare workers and individuals with previous COVID-19 infections may experience more severe side effects after vaccination.

VACCINES (2021)

添加到收藏夹

Article Medicine, General & Internal

Global Incidence of Neurological Manifestations Among Patients Hospitalized With COVID-19-A Report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium

Sherry H. -Y. Chou et al.

Summary: This study included patients with clinically diagnosed or laboratory-confirmed COVID-19 at 28 centers across 13 countries and 4 continents from March 1 to September 30, 2020. Neurological manifestations were prevalent among hospitalized patients with COVID-19 and were associated with higher in-hospital mortality. Patients with preexisting neurological disorders were at increased risk of developing neurological signs and/or syndromes in COVID-19.

JAMA NETWORK OPEN (2021)

添加到收藏夹

Article Medicine, General & Internal

Minor to Moderate Side Effects of Pfizer-BioNTech COVID-19 Vaccine Among Saudi Residents: A Retrospective Cross-Sectional Study

Nagla A. El-Shitany et al.

Summary: This study tracked the short-term side effects of the Pfizer vaccine, finding common symptoms to include injection site pain, headaches, and fever. Females and individuals previously infected with the coronavirus were more likely to experience side effects.

INTERNATIONAL JOURNAL OF GENERAL MEDICINE (2021)

添加到收藏夹

Article Immunology

Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV

Jake A. Ruddy et al.

Summary: This study found uniformly high anti-SARS-CoV-2 receptor binding domain (RBD) antibody titres in 14 persons with HIV after two doses of mRNA vaccination, despite varied titres after a single dose. The majority of vaccine reactions were mild and no adverse events occurred.

AIDS (2021)

添加到收藏夹

Article Rheumatology

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study

Victoria Furer et al.

Summary: Vaccination with mRNA BNT162b2 vaccine showed reduced immunogenicity in patients with AIIRD compared to the general population, with risk factors including older age and treatment with glucocorticoids, rituximab, mycophenolate mofetil (MMF), and abatacept. However, most patients maintained stable disease activity post-vaccination.

ANNALS OF THE RHEUMATIC DISEASES (2021)

添加到收藏夹

Article Obstetrics & Gynecology

Maternal and Child Symptoms Following COVID-19 Vaccination Among Breastfeeding Mothers

Skyler McLaurin-Jiang et al.

Summary: This study found that COVID-19 vaccination among breastfeeding mothers had minimal disruption of lactation or adverse impact on the breastfed child. Even among mothers who reported an adverse impact on breastfeeding, their opinion about vaccination and confidence in their decision to receive the COVID-19 vaccine remained high.

BREASTFEEDING MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial

Ya-Jun Shu et al.

Summary: This study evaluated the immunogenicity and safety of the V-01 vaccine, showing that it induced robust immune responses in the two-dose regimen and demonstrated high safety levels. The older adult group exhibited a more favorable safety profile compared to the younger adult group.

CHINESE MEDICAL JOURNAL (2021)

添加到收藏夹

Article Immunology

Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: A nationwide descriptive study

Miguel Garcia-Grimshaw et al.

Summary: mRNA vaccines against SARS-CoV-2 are shown to be safe and effective, with low incidence of adverse events post-immunization, most of which are non-serious, with neurologic AEFIs being the majority. The vaccines offer significant individual and societal benefits, outweighing the low percentage of serious neurologic AEFIs, which should help dispel hesitancy towards this new vaccine platform.

CLINICAL IMMUNOLOGY (2021)

添加到收藏夹

Article Behavioral Sciences

COVID-19 vaccination in patients with epilepsy: First experiences in a German tertiary epilepsy center

Randi von Wrede et al.

Summary: In this study, 54 patients with epilepsy who received their first COVID-19 vaccination were assessed. Two thirds showed good tolerance to the vaccine, with about one third reporting general adverse effects. Only one patient reported increased seizure frequency after vaccination among the epilepsy patients.

EPILEPSY & BEHAVIOR (2021)

添加到收藏夹

Article Clinical Neurology

Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel

Itay Lotan et al.

Summary: The study reported real-life safety data of the BNT162b2 COVID-19 vaccine in a cohort of MS patients. Most adverse events occurred within the first 24 hours after vaccination and resolved within 3 days, with the majority of patients not requiring medication for their symptoms. Further large-scale studies are needed to confirm these findings.

EUROPEAN JOURNAL OF NEUROLOGY (2021)

添加到收藏夹

Article Infectious Diseases

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March-June 2021, England

Annabel A. Powell et al.

Summary: Adults receiving heterologous COVID-19 immunisation with mRNA or adenoviral-vector vaccines had higher reactogenicity rates, especially among those aged over 50, women, and individuals with prior symptomatic/confirmed COVID-19. Those who received heterologous schedules after severe first-dose reactions may have lower reactogenicity after the second dose, depending on the specific combination of vaccines used.

EUROSURVEILLANCE (2021)

添加到收藏夹

Article Medicine, General & Internal

Adverse reactions to Pfizer-BioNTech vaccination of healthcare workers at Malta's state hospital

Sarah Cuschieri et al.

Summary: The study in Malta examined adverse effects of the Pfizer-BioNTech COVID-19 vaccine on healthcare workers. The most common adverse effects were pain at the injection site, mainly mild or moderate, with females having a higher susceptibility to various symptoms. Overall, the low occurrence of adverse effects should help alleviate vaccine hesitancy in the population.

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Myocarditis and Pericarditis After Vaccination for COVID-19

George A. Diaz et al.

Summary: This study compares the incidence of myocarditis and pericarditis in emergency department or inpatient hospital encounters before and during the period of COVID-19 vaccination availability in a large US health care system.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults A Randomized Clinical Trial

Nawal Al Kaabi et al.

Summary: This interim analysis of an ongoing randomized trial in the UAE and Bahrain evaluated the efficacy of two inactivated COVID-19 vaccines in preventing symptomatic cases and adverse events in healthy adults. The study found that both vaccines significantly reduced the risk of symptomatic COVID-19 compared to the control group, with efficacy rates of 72.8% and 78.1%. Serious adverse events were rare across all groups.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Clinical Neurology

Delayed headache after COVID-19 vaccination: a red flag for vaccine induced cerebral venous thrombosis

David Garcia-Azorin et al.

Summary: Cerebral venous thrombosis (CVT) can occur following COVID-19 vaccination, especially in recipients of adenovirus vector-based vaccines. Headache is a common symptom of CVT, associated with intracranial hemorrhage but not directly linked to death.

JOURNAL OF HEADACHE AND PAIN (2021)

添加到收藏夹

Article Virology

Safety of COVID-19 vaccines

Qutaiba A. Al Khames Aga et al.

Summary: This study investigated the adverse effects associated with three different COVID-19 vaccines and found that local reactions were more common with Pfizer and AstraZeneca vaccines, while systemic events were more prevalent with AstraZeneca and Pfizer vaccines. There was no correlation between age or gender and the duration of adverse effects, and some participants reported unusual symptoms like swelling of eyelids and severe allergic reactions. Overall, Pfizer, AstraZeneca, and Sinopharm vaccines were deemed safe, with Sinopharm showing lower prevalence of adverse effects compared to the others.

JOURNAL OF MEDICAL VIROLOGY (2021)

添加到收藏夹

Article Public, Environmental & Occupational Health

Side Effects after Second Dose of Covishield Vaccine among Healthcare Workers: A Descriptive Cross-sectional Study

Khilasa Pokharel et al.

Summary: The study aimed to identify the side effects experienced by healthcare workers after receiving the second dose of the Covishield vaccine. The most common side effects reported were pain at the injection site, fatigue, and headache.

JOURNAL OF NEPAL MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

Alberto M. Borobia et al.

Summary: To date, there are no immunological data on COVID-19 heterologous vaccination schedules in humans. This study evaluated the immunogenicity and reactogenicity of administering BNT162b2 as a second dose in individuals primed with ChAdOx1-S. The results showed that BNT162b2 induced a robust immune response in individuals prime vaccinated with ChAdOx1-S, with an acceptable and manageable reactogenicity profile.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

Mine Durusu Tanriover et al.

Summary: The study presented the interim efficacy and safety results of the CoronaVac vaccine in a phase 3 clinical trial in Turkey, demonstrating high efficacy against PCR-confirmed symptomatic COVID-19 with good safety and tolerability profile. Results showed significant differences in the frequency of any adverse events between the vaccine and placebo groups, indicating excellent protective effects of the vaccine.

LANCET (2021)

添加到收藏夹

Article Infectious Diseases

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial

Bihua Han et al.

Summary: The study evaluated the safety, tolerability, and immunogenicity of the candidate COVID-19 vaccine CoronaVac containing inactivated SARS-CoV-2 in children and adolescents aged 3-17 years. The research findings indicate that the 3.0 μg dose induced higher levels of neutralizing antibodies compared to the 1.5 μg dose, supporting the use of the 3.0 μg dose for further studies in this age group.

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Biotechnology & Applied Microbiology

A comprehensive analysis of the efficacy and safety of COVID-19 vaccines

Changjing Cai et al.

Summary: The numbers of COVID-19 cases and deaths are increasing, with vaccine efficacy exceeding 70% and RNA-based vaccines being the most effective at 94.29%. The most common vaccine-related adverse reactions are pain, fatigue, and headache, with most reactions being mild, although severe reactions such as thromboembolic events have been identified.

MOLECULAR THERAPY (2021)

添加到收藏夹

Editorial Material Clinical Neurology

Underdiagnosis and undertreatment of migraine in Poland

Olga P. Fermo

NEUROLOGIA I NEUROCHIRURGIA POLSKA (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

Robert W. Frenck et al.

Summary: The BNT162b2 vaccine showed favorable safety profile and a greater immune response in 12-to-15-year-old recipients compared to young adults, and demonstrated high effectiveness against Covid-19.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

Paul T. Heath et al.

Summary: The NVX-CoV2373 vaccine demonstrated an efficacy of 89.7% in a phase 3 trial with over 15,000 participants, with mild and transient reactogenicity. It showed high efficacy against the B.1.1.7 variant and a low incidence of adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Letter Medicine, General & Internal

Vaccine-Induced Thrombocytopenia with Severe Headache

Farid Salih et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

ChAdOx1 COVID-19 vaccine-induced thrombocytopenia syndrome

Y-H Wang et al.

QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Rheumatology

Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey

Somy Cherian et al.

Summary: The study found that there were no significant differences in adverse reaction rates between patients with autoimmune rheumatic diseases (AIRD) and non-AIRD after receiving the ChAdOx1 or BBV152 vaccines, confirming the safety of the vaccines in rheumatic and musculoskeletal diseases (RMDs).

RHEUMATOLOGY INTERNATIONAL (2021)

添加到收藏夹

Article Hematology

Absence of hypercoagulability after nCoV-19 vaccination: An observational pilot study

Elena Campello et al.

Summary: The study evaluated the coagulation profile in healthy subjects who received the first dose of BNT162b2 or ChAdOx1 vaccines, finding no significant hypercoagulable state induced by the vaccines. Results remained consistent even after controlling for variables such as age, gender, and hormonal factors.

THROMBOSIS RESEARCH (2021)

添加到收藏夹

Article Immunology

Immunogenicity and Reactogenicity After SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Taking Belatacept

Michael T. Ou et al.

Summary: The study examined the immunogenicity after SARS-CoV-2 mRNA vaccines in kidney transplant recipients taking belatacept and those who are not. Belatacept use was associated with lower odds of having a positive post-D2 titer result, indicating the need for additional measures to protect kidney transplant recipients taking belatacept.

TRANSPLANTATION (2021)

添加到收藏夹

Article Acoustics

Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine

S. Bookstein Peretz et al.

Summary: This observational study compared the immunogenicity and reactogenicity of the Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine between pregnant and non-pregnant women. The study found that pregnant women experienced similar rates of adverse effects following vaccination as non-pregnant women, with lower levels of SARS-CoV-2 IgG. The vaccine was effective in generating a humoral immune response in pregnant women, with no safety concerns identified.

ULTRASOUND IN OBSTETRICS & GYNECOLOGY (2021)

添加到收藏夹

Article Immunology

Tolerance of BNT162b2 mRNA COVI-19 vaccine in patients with a medical history of COVID-19 disease: A case control study

Aurelie Baldolli et al.

Summary: The study found that individuals with a history of COVID-19 infection are more likely to experience systemic reactions and symptoms like fatigue, headache, and fever after receiving the BNT162b2 mRNA Covid-19 vaccine. Although these individuals had higher severity of reactions, overall tolerance was good.

VACCINE (2021)

添加到收藏夹

News Item Medicine, General & Internal

Covid-19: Regulators warn that rare Guillain-Barre cases may link to J&J and AstraZeneca vaccines

Owen Dyer

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Article Cell Biology

Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients

Cristina Bergamaschi et al.

Summary: Early responses to vaccination play a crucial role in shaping both humoral and cellular protective immunity. This study characterizes cytokine and chemokine responses after the first and second dose of the BNT162b2 mRNA vaccine, highlighting the potential for biomarkers like IL-15 and IFN-gamma in predicting humoral immunity development. In previously COVID-19-infected individuals, a single vaccination can trigger strong cytokine induction and antibody responses similar to those seen in naive individuals upon booster vaccination, with implications for future public health recommendations.

CELL REPORTS (2021)

添加到收藏夹

Article Environmental Sciences

Subjective Feelings of Polish Doctors after Receiving the COVID-19 Vaccine

Krzysztof Zdziarski et al.

Summary: The global pandemic has caused chaos in our daily lives, but the vaccine offers hope. Research shows that doctors are generally optimistic about the vaccine, although some still have concerns and fears.

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2021)

添加到收藏夹

Article Medicine, General & Internal

Can reactogenicity predict immunogenicity after COVID-19 vaccination?

Young Hoon Hwang et al.

Summary: This study found no significant association between the severity of local and systemic adverse events and humoral immunogenicity after SARS-CoV-2 vaccination.

KOREAN JOURNAL OF INTERNAL MEDICINE (2021)

添加到收藏夹

Article Public, Environmental & Occupational Health

Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021

Heather M. Scobie et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

添加到收藏夹

Article Medicine, General & Internal

Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey

Abanoub Riad et al.

Summary: COVID-19 vaccine hesitancy poses a serious threat to achieving community immunity through mass vaccination. Independent studies on vaccine side effects can help boost public confidence and uptake. A study in Turkish healthcare workers found a higher prevalence of CoronaVac side effects compared to clinical trials, with factors like gender and health status potentially impacting the risk of side effects.

JOURNAL OF CLINICAL MEDICINE (2021)

添加到收藏夹

Article Immunology

Pfizer-BioNTech COVID-19 Vaccine Tolerance in Allergic versus Non-Allergic Individuals

Marita Nittner-Marszalska et al.

Summary: The study examined the tolerance of allergic patients to the Pfizer-BioNTech vaccine through an online questionnaire. Results showed that allergic individuals were more likely to experience local and systemic adverse reactions after vaccination, but these reactions were mild and did not prevent successful completion of the vaccination cycle.

VACCINES (2021)

添加到收藏夹

Article Immunology

Side Effects Reported by Jordanian Healthcare Workers Who Received COVID-19 Vaccines

Osama Abu-Hammad et al.

Summary: The survey conducted among healthcare professionals who received COVID-19 vaccines in Jordan showed that around 18% and 31% reported no side effects after the first and second doses respectively. Most of the side effects were local, while systemic side effects like fatigue, myalgia, headache, and fever were more common after the first dose, particularly associated with the AstraZeneca vaccine and age <= 45 years. No serious side effects were reported, indicating that the side effects of COVID-19 vaccines in Jordan are similar to what have been known before. Further studies with larger sample sizes and longer follow-up periods are needed to monitor potential serious and long-term side effects.

VACCINES (2021)

添加到收藏夹

Article Immunology

Neutralizing Antibodies Titers and Side Effects in Response to BNT162b2 Vaccine in Healthcare Workers with and without Prior SARS-CoV-2 Infection

Jose Javier Morales-Nunez et al.

Summary: The study evaluated the efficacy of the Pfizer-BioNTech vaccine in producing neutralizing antibodies, finding 100% production after the second dose in both groups and well-tolerated side effects. Additionally, a single dose of the vaccine may be sufficient for immunity in individuals with prior COVID-19 infection, with possible signs of immunosenescence.

VACCINES (2021)

添加到收藏夹

Article Immunology

Evaluation of Side Effects Associated with COVID-19 Vaccines in Saudi Arabia

Abdulaziz Alhazmi et al.

Summary: A study conducted in Saudi Arabia found that side effects reported after receiving Oxford-AstraZeneca and Pfizer-BioNTech vaccines are similar to those reported in clinical trials, indicating the safety of these vaccines. Most participants reported fatigue and pain at the injection site as common side effects. Further research is needed to assess the effectiveness of these vaccines in protecting against SARS-CoV-2 reinfections.

VACCINES (2021)

添加到收藏夹

Article Immunology

Side Effects and Perceptions Following COVID-19 Vaccination in Jordan: A Randomized, Cross-Sectional Study Implementing Machine Learning for Predicting Severity of Side Effects

Ma'mon M. Hatmal et al.

Summary: The study confirms the safety of authorized COVID-19 vaccines, with most side effects being mild to moderate, indicating the body's immune system is building protection. Many individuals feel more reassured after vaccination and recommend others to get vaccinated.

VACCINES (2021)

添加到收藏夹

Article Immunology

Impacts of Side Effects to BNT162b2 and the First Dose of ChAdOx1 Anti-SARS-CoV-2 Vaccination on Work Productivity, the Need for Medical Attention, and Vaccine Acceptance: A Multicenter Survey on Healthcare Workers in Referral Teaching Hospitals in the Republic of Korea

Tark Kim et al.

Summary: A survey on vaccinated healthcare workers in South Korea revealed that individuals who received the AstraZeneca vaccine (ChAdOx1) reported more side effects and impacts on work productivity compared to those who received the Pfizer-BioNTech vaccine (BNT162b2). However, for individuals aged 40 and above, there was no significant difference in work absenteeism or hospitalization between the two vaccines. Older healthcare workers in the ChAdOx1 group showed intention to receive the second dose, and the impact of side effects seemed to be rare in this age group, regardless of the vaccine received.

VACCINES (2021)

添加到收藏夹

Article Clinical Neurology

Headache Attributed to Vaccination Against COVID-19 (Coronavirus SARS-CoV-2) with the ChAdOx1 nCoV-19 (AZD1222) Vaccine: A Multicenter Observational Cohort Study

Carl H. Goebel et al.

Summary: Headaches attributed to vaccination with ChAdOx1 nCoV-19 (AZD1222) demonstrate a complex of symptoms including bilateral location on the forehead and temples, pressing or dull pain character, and accompanying symptoms like fatigue, chills, exhaustion, and fever. These findings have important clinical implications for the differentiation of post-vaccinal headache from other primary and secondary headaches.

PAIN AND THERAPY (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

Allergic Reactions After COVID-19 Vaccination-Putting Risk Into Perspective

Elizabeth J. Phillips

JAMA NETWORK OPEN (2021)

添加到收藏夹

Article Clinical Neurology

Clinical characteristics of headache after vaccination against COVID-19 (coronavirus SARS-CoV-2) with the BNT162b2 mRNA vaccine: a multicentre observational cohort study

Carl H. Goebel et al.

Summary: The study aims to examine in detail the clinical characteristics of headaches occurring after vaccination against COVID-19 with the BNT162b2 mRNA vaccine. Results show that headaches typically occur around 18 hours after vaccination and last about 14 hours, with most being bilateral and located in the forehead and temples. The pain is usually pressing in nature, and common accompanying symptoms include fatigue, exhaustion, and muscle pain.

BRAIN COMMUNICATIONS (2021)

添加到收藏夹

Article Medicine, General & Internal

Early Safety Monitoring of COVID-19 Vaccines in Healthcare Workers

Joon Young Song et al.

Summary: Hospital-based surveillance found that healthcare workers who received the adenovirus-vectored COVID-19 vaccine experienced higher rates of systemic adverse events compared to mRNA vaccine recipients. Common adverse events among adenovirus-vectored vaccine recipients included fatigue, myalgia, headache, and fever, with most symptoms resolving within 2 days. Both COVID-19 vaccines were generally safe with few serious adverse events reported.

JOURNAL OF KOREAN MEDICAL SCIENCE (2021)

添加到收藏夹

Article Medicine, General & Internal

Bilateral Thalamic Stroke: A Case of COVID-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) or a Coincidence Due to Underlying Risk Factors?

Richard Giovane et al.

Summary: VITT is a rare but potentially life-threatening immune response to COVID-19 vaccines, characterized by thrombosis, thrombocytopenia, and coagulation abnormalities, but vaccination is still considered crucial in overcoming the pandemic.

CUREUS JOURNAL OF MEDICAL SCIENCE (2021)

添加到收藏夹

Article Primary Health Care

2019 Novel Coronavirus Vaccination among Post-graduate Residents and Fellows

Mostafa Abohelwa et al.

Summary: Most medical trainees show a high interest in COVID-19 vaccination, although there are a few who do not wish to be vaccinated. After vaccination, residents and fellows reported various side effects such as pain, redness, fever, and fatigue.

JOURNAL OF PRIMARY CARE AND COMMUNITY HEALTH (2021)

添加到收藏夹

Article Immunology

Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial

Yuyi Liao et al.

Summary: Safe and effective V-01 vaccine has been developed and progressed to Phase I clinical trials, showing promising safety profile and rapid, strong immune responses. The vaccine induced high-titre neutralizing antibodies and anti-RBD IgG, with encouraging immunogenicity in low dose subgroup and elderly participants, indicating great potential as a vaccine against COVID-19 for all-aged population.

EMERGING MICROBES & INFECTIONS (2021)

添加到收藏夹

Article Medicine, General & Internal

Emergency Department Utilization by In-hospital Healthcare Workers after COVID-19 Vaccination

Min Ji Park et al.

Summary: In this observational study analyzing emergency department utilization patterns of COVID-19 vaccinated healthcare workers, it was found that fever and myalgia were common symptoms among those who visited the ED. However, most cases did not result in serious illnesses. As the COVID-19 vaccination program continues to expand in Korea, strategies should be implemented to minimize unnecessary ED overcrowding.

JOURNAL OF KOREAN MEDICAL SCIENCE (2021)

添加到收藏夹

Article Medicine, General & Internal

Association between previous infection with SARS CoV-2 and the risk of self-reported symptoms after mRNA BNT162b2 vaccination: Data from 3,078 health care workers

Antonella d'Arminio Monforte et al.

Summary: The study found that healthcare workers with a history of COVID-19 are more likely to experience severe and moderate systemic symptoms after vaccination, but no severe adverse events were reported.

ECLINICALMEDICINE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials

Fan-Yue Meng et al.

Summary: The vaccine was tested in two trials in China, showing that after three doses, it is safe and induces significant immune responses in healthy individuals aged 18 and older.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial

Wanshen Guo et al.

Summary: The study assessed the safety and immunogenicity of an inactivated COVID-19 vaccine in Chinese adults, showing it to be well tolerated and immunogenic in both younger and older adults. Different dosing schedules were evaluated and could be further assessed for long-term safety and efficacy in phase 3 trials.

ECLINICALMEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Adverse Reactions of the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers in Korea

Yun Woo Lee et al.

Summary: This study found that the rate of adverse reactions in healthcare workers after receiving both doses of the BNT162b2 mRNA vaccine significantly increased after the second dose, especially muscle ache, fatigue, headache, chills, and fever. Females had a significantly higher frequency of adverse reactions after the second dose, while older age groups had lower rates of adverse reactions.

JOURNAL OF KOREAN MEDICAL SCIENCE (2021)

添加到收藏夹

Article Medicine, General & Internal

Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials

Hong-Xing Pan et al.

Summary: This study reported the immunogenicity and safety of an inactivated SARS-CoV-2 vaccine, KCONVAC, in healthy adults. The vaccine demonstrated good tolerability and induced robust immune responses in both phase 1 and phase 2 trials.

CHINESE MEDICAL JOURNAL (2021)

添加到收藏夹

Article Medicine, General & Internal

Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System

Minji Jeon et al.

Summary: The study focused on investigating adverse events following immunization (AEFIs) for COVID-19 among healthcare workers (HCWs) who received the ChAdOx1 nCoV-19 vaccine. The majority of AEFIs reported were mild-to-moderate in severity, with older age groups experiencing fewer and less severe AEFIs. No serious events requiring hospitalization were reported, and most AEFIs resolved within a few days. The use of the Mobile Vaccine Adverse Events Reporting System (MVAERS) was found to be helpful in monitoring and sharing accurate information about vaccination against COVID-19.

JOURNAL OF KOREAN MEDICAL SCIENCE (2021)

添加到收藏夹

Article Medicine, General & Internal

Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience

Si Ho Kim et al.

Summary: The study in South Korea on healthcare workers receiving COVID-19 vaccinations showed that more adverse events were reported in ChAdOx1 nCoV-19 recipients compared to BNT162b2 recipients. However, most reported adverse events were mild to moderate in severity, emphasizing the importance of providing sufficient explanation and preparation for expected adverse events to promote widespread vaccination.

JOURNAL OF KOREAN MEDICAL SCIENCE (2021)

添加到收藏夹

Article Medicine, General & Internal

Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea

Seongman Bae et al.

Summary: A prospective survey conducted in South Korea on healthcare workers who received the first dose of two COVID-19 vaccines showed a higher rate of adverse reactions in the ChAdOx1 group compared to the BNT162b2 group. Females and younger age groups were more likely to experience vaccine-associated adverse reactions.

JOURNAL OF KOREAN MEDICAL SCIENCE (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial

Pablo Tebas et al.

Summary: The study found that the INO-4800 vaccine performed well in inducing immune responses and had good safety, with no serious adverse events reported. Participants exhibited both cellular and humoral immune responses to the vaccine, indicating its effectiveness in eliciting immunity.

ECLINICALMEDICINE (2021)

添加到收藏夹

Editorial Material Biochemistry & Molecular Biology

Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms

Abdul Mannan Baig et al.

ACS CHEMICAL NEUROSCIENCE (2020)

添加到收藏夹

Letter Immunology

Nervous system damage after COVID-19 infection: Presence or absence?

Yeshun Wu et al.

BRAIN BEHAVIOR AND IMMUNITY (2020)

添加到收藏夹

Article Immunology

Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection

Claudio Liguori et al.

BRAIN BEHAVIOR AND IMMUNITY (2020)

添加到收藏夹

Article Clinical Neurology

COVID-19 is a Real Headache!

Hayrunnisa Bolay et al.

HEADACHE (2020)

添加到收藏夹

Editorial Material Clinical Neurology

Headache medication and the COVID-19 pandemic

Antoinette MaassenVanDenBrink et al.

JOURNAL OF HEADACHE AND PAIN (2020)

添加到收藏夹

Article Medicine, General & Internal

Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019

Jerome R. Lechien et al.

JOURNAL OF INTERNAL MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Feng-Cai Zhu et al.

LANCET (2020)

添加到收藏夹

Review Medicine, General & Internal

Novel Coronavirus Infection (COVID-19) in Humans: A Scoping Review and Meta-Analysis

Israel Junior Borges do Nascimento et al.

JOURNAL OF CLINICAL MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes Interim Analysis of 2 Randomized Clinical Trials

Shengli Xia et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

添加到收藏夹

Article Medicine, General & Internal

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Feng-Cai Zhu et al.

LANCET (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

Mark J. Mulligan et al.

NATURE (2020)

添加到收藏夹

Article Medicine, General & Internal

An mRNA Vaccine against SARS-CoV-2-Preliminary Report

L. A. Jackson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Denis Y. Logunov et al.

LANCET (2020)

添加到收藏夹

Article Multidisciplinary Sciences

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Ugur Sahin et al.

NATURE (2020)

添加到收藏夹

Article Medicine, General & Internal

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

E. J. Anderson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Cheryl Keech et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Editorial Material Clinical Neurology

Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019

T. J. Steiner et al.

JOURNAL OF HEADACHE AND PAIN (2020)

添加到收藏夹

Article Immunology

Innate Immune Responses to Chimpanzee Adenovirus Vector 155 Vaccination in Mice and Monkeys

Catherine Collignon et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Review Cell Biology

Coronavirus vaccine development: from SARS and MERS to COVID-19

Yen-Der Li et al.

JOURNAL OF BIOMEDICAL SCIENCE (2020)

添加到收藏夹

Article Clinical Neurology

Phenotypic characterization of acute headache attributed to SARS-CoV-2: An ICHD-3 validation study on 106 hospitalized patients

Javier Trigo Lopez et al.

CEPHALALGIA (2020)

添加到收藏夹

Article Clinical Neurology

Headache yesterday in Karnataka state, India: prevalence, impact and cost

Timothy J. Steiner et al.

JOURNAL OF HEADACHE AND PAIN (2016)

添加到收藏夹

Review Medicine, General & Internal

Rayyan-a web and mobile app for systematic reviews

Mourad Ouzzani et al.

SYSTEMATIC REVIEWS (2016)

添加到收藏夹

Article Clinical Neurology

Headache yesterday in Russia: its prevalence and impact, and their application in estimating the national burden attributable to headache disorders

Ilya Ayzenberg et al.

JOURNAL OF HEADACHE AND PAIN (2015)

添加到收藏夹

Article Clinical Neurology

Lifetime prevalence and underdiagnosis of migraine in a population sample of Mexican women

C. Arroyo-Quiroz et al.

CEPHALALGIA (2014)

添加到收藏夹

Article Clinical Neurology

Headache yesterday in Europe

Colette Andree et al.

JOURNAL OF HEADACHE AND PAIN (2014)

添加到收藏夹

Article Clinical Neurology

Headache yesterday in China: A new approach to estimating the burden of headache, applied in a general-population survey in China

Shengyuan Yu et al.

CEPHALALGIA (2013)

添加到收藏夹

Article Immunology

Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults

Stephanie Pepin et al.

VACCINE (2013)

添加到收藏夹

Article Medicine, General & Internal

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

David Moher et al.

ANNALS OF INTERNAL MEDICINE (2009)

添加到收藏夹

Article Medicine, General & Internal

Measuring inconsistency in meta-analyses

JPT Higgins et al.

BMJ-BRITISH MEDICAL JOURNAL (2003)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.